Who
James Rolke
Chief Executive Officer
Company insider
Files Form 4 as: Chief Executive Officer, Revelation Biosciences; Chief Scientific Officer, La Jolla Pharmaceutical Co.
In numbers
- Trades disclosed
- 94
- Buys
- 2
- Sells
- 0
- Bought
- $32K
- Sold
- $0
- Companies
- 2
- Companies where not an officer
- 0
- First trade
- 4 Jan 2017
- Last trade
- 17 Aug 2026
- Last filed
- 18 Aug 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 17 Aug 2026filed 18 Aug 2026 | REVB Revelation BiosciencesBiotechnology | SEC FORM 4 Code A | —208,076 at $0.00 | filing |
| 17 Aug 2026filed 18 Aug 2026 | REVB Revelation BiosciencesBiotechnology | SEC FORM 4 Code A | —208,076 at $0.00 | filing |
| 30 Apr 2026filed 1 May 2026 | REVB Revelation BiosciencesBiotechnology | SEC FORM 4 Code F | $11K10,115 at $1.13 | filing |
| 30 Apr 2026filed 1 May 2026 | REVB Revelation BiosciencesBiotechnology | SEC FORM 4 Code F | $11K10,115 at $1.13 | filing |
| 3 Feb 2026filed 5 Feb 2026 | REVB Revelation BiosciencesBiotechnology | SEC FORM 4 Code F | $16K8,521 at $1.86 | filing |
| 3 Feb 2026filed 5 Feb 2026 | REVB Revelation BiosciencesBiotechnology | SEC FORM 4 Code F | $16K8,521 at $1.86 | filing |
| 8 Jan 2026filed 12 Jan 2026 | REVB Revelation BiosciencesBiotechnology | SEC FORM 4 Code A | $480K532,829 at $0.90 | filing |
| 8 Jan 2026filed 12 Jan 2026 | REVB Revelation BiosciencesBiotechnology | SEC FORM 4 Code A | $480K532,829 at $0.90 | filing |
| 29 Oct 2025filed 31 Oct 2025 | REVB Revelation BiosciencesBiotechnology | SEC FORM 4 Code A | $500K390,614 at $1.28 | filing |
| 11 Feb 2025filed 13 Feb 2025 | REVB Revelation BiosciencesBiotechnology | SEC FORM 4 Code A | $116K30,095 at $3.87 | filing |
| 25 Feb 2023filed 28 Feb 2023 | REVB Revelation Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —2,542 at $0.00 | filing |
| 29 May 2020filed 2 Jun 2020 | La Jolla Pharmaceutical Cooption or derivative | SEC FORM 4 Code A | —205 at $0.00 | filing |
| 29 May 2020filed 2 Jun 2020 | La Jolla Pharmaceutical Co | SEC FORM 4 Code A | $822205 at $4.01 | filing |
| 15 May 2020filed 19 May 2020 | La Jolla Pharmaceutical Cooption or derivative | SEC FORM 4 Code A | —140 at $0.00 | filing |
| 15 May 2020filed 19 May 2020 | La Jolla Pharmaceutical Co | SEC FORM 4 Code A | $820140 at $5.86 | filing |
| 30 Apr 2020filed 4 May 2020 | La Jolla Pharmaceutical Cooption or derivative | SEC FORM 4 Code A | —133 at $0.00 | filing |
| 30 Apr 2020filed 4 May 2020 | La Jolla Pharmaceutical Co | SEC FORM 4 Code A | $821133 at $6.17 | filing |
| 15 Apr 2020filed 17 Apr 2020 | La Jolla Pharmaceutical Cooption or derivative | SEC FORM 4 Code A | —146 at $0.00 | filing |
| 15 Apr 2020filed 17 Apr 2020 | La Jolla Pharmaceutical Co | SEC FORM 4 Code A | $819146 at $5.61 | filing |
| 31 Mar 2020filed 2 Apr 2020 | La Jolla Pharmaceutical Cooption or derivative | SEC FORM 4 Code A | —229 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.